Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ren, Xiang Shan ^a,b   Sato, Yasunori ^a   Harada, Kenichi ^a   Sasaki, Motoko ^a   Furubo, Shinichi ^a   Song, Jing Yu ^b   Nakanuma, Yasuni ^a,c  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b YANBIAN UNIVERSITY   (China)

^c SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 METHYLADENINE; DACTOLISIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; BILE DUCT CYST; CELL PROLIFERATION; CELL TYPE; CHOLANGIOCYTE; CONTROLLED STUDY; INTRAHEPATIC BILE DUCT; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; CELLS, CULTURED; PHOSPHATIDYLINOSITOL 3-KINASE; POLYCYSTIC KIDNEY DISEASES; RATS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84900423162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087660     Document Type: Article

References (34)

1. Nakanuma Y, Harada K, Sato Y, Ikeda H (2010) Recent progress in the etiopathogenesis of pediatric biliary disease, particularly Caroli's disease with congenital hepatic fibrosis and biliary atresia. Histol Histopathol 25: 223-235.
2. Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60: 321-337.
3. Sanzen T, Harada K, Yasoshima M, Kawamura Y, Ishibashi M, et al. (2001) Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis. Am J Pathol. 158: 1605-1612. (Pubitemid 32422925)
4. Sato Y, Ren XS, Nakanuma Y (2012) Caroli's disease: current knowledge of its biliary pathogenesis obtained from an orthologous rat model. Int J Hepatol.
5. Zhou H, Huang S (2010) The complexes of mammalian target of rapamycin. Curr Protein Pept Sci. 11: 409-424.
6. Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69: 1821-1827.
7. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, et al. (2010) Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology. 51: 1778-1788.
8. Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 21: 489-497.
9. Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL (2010) Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 78: 754-761.
10. Walz G (2006) Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol Dial Transplant 21: 1752-1757.
11. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471.
12. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, et al. (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 363: 820-829.
13. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, et al. (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 363: 830-840.
14. Renken C, Fischer DC, Kundt G, Gretz N, Haffner D (2011) Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant. 26: 92-100.
15. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, et al. (2009) Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 24: 1819-1827.
16. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, et al. (2010) Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 70: 8097-8107.
17. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, et al. (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 8: 2204-2210.
18. Zhou XJ, Kukes G (1998) Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Diagn Mol Pathol 7: 65-68. (Pubitemid 28443092)
19. Lanoix J, D'Agati V, Szabolcs M, Trudel M (1996) Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 13: 1153-1160. (Pubitemid 26343568)
20. Woo D (1995) Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333: 18-25.
21. Hu B, He X, Li A, Qiu Q, Li C, et al. (2011) Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys. Exp Cell Res 317: 173-187.
22. Belibi F, Zafar I, Ravichandran K, Segvic AB, Jani A, et al. (2011) Hypoxia-inducible factor-1a (HIF-1a) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol. 300:F1235-1243.
23. Sato Y, Harada K, Kizawa K, Sanzen T, Furubo S, et al. (2005) Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease. Am J Pathol 166: 49-60. (Pubitemid 40051659)
24. Ren XS, Sato Y, Harada K, Sasaki M, Yoneda N, et al. (2011) Biliary infection may exacerbate biliary cystogenesis through the induction of VEGF in cholangiocytes of the polycystic kidney (PCK) rat. Am J Pathol. 179: 2845-2854.
25. Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, et al. (2012) V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology. 55: 1473-1484.
26. Edelstein CL (2008) Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol. 3: 1219-1226.
27. Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T (2011) Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol Rep. 26: 1273-1279.
28. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, et al. (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res. 17: 2373-2384.
29. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, et al. (2012) Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 21: 227-239.
30. Wang X, Proud CG (2011) mTORC1 signaling: what we still don't know. J Mol Cell Biol. 3: 206-220.
31. Sini P, James D, Chresta C, Guichard S (2010) Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy. 6: 553-554.
32. Foster DA, Toschi A (2009) Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 8: 1026-1029.
33. Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, et al. (2011) S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One. 6:e27509.
34. Sato Y, Harada K, Furubo S, Kizawa K, Sanzen T, et al. (2006) Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib. Am J Pathol. 169: 1238-1250. (Pubitemid 351194360)